



# MOLECULAR BIOLOGY

Applied to Clinical Oncology

## International Diploma in Molecular Biology Applied to Clinical Oncology (Fifth edition 2022)

### Background

The main objective of the International Diploma in Molecular Biology Applied to Clinical Oncology is to provide an excellence international educational program with high academic and professional European experts in the different oncological areas for the diagnosis and treatment of cancer-based on molecular biology. Link: [www.internationaloncologydiploma.com](http://www.internationaloncologydiploma.com)

### Academic Endorsement

The present program has the following endorsements:

- GIGA Cancer Center Institute. Liege University (Link: [http://www.giga.uliege.be/cms/j\\_6/fr/accueil-internet](http://www.giga.uliege.be/cms/j_6/fr/accueil-internet))
- University Hospital Center of Liège CHU Liege (Link: [http://www.chu.ulg.ac.be/jcms/r\\_127200/fr/internet-accueil](http://www.chu.ulg.ac.be/jcms/r_127200/fr/internet-accueil))
- Belgian Society of Medical Oncology (Link: [www.bsmo.be](http://www.bsmo.be))
- European Cancer Organization (Link: <https://www.europeancancer.org/>)
- ACOE Accreditation by European Cancer Organization (Link: <https://acoe.europeancancer.org/>)

Organize: Health & Research Services: [www.hrservicesec.com](http://www.hrservicesec.com)

Program Duration:	6 months (15 of October 2022 to 17 of April 2023)
Academic Hours:	<b>200 hours, 61 CME European Credits</b>
Modality:	<b>In class sessions: 11-12 of March 2023 (Lima, Peru)</b> and Zoom interactive meetings and on-line videos
Program Language:	English and Spanish
Mobile App:	Molecular Oncology

### Cost

Inscription: 2,500 USD (includes program access with educational materials, educational platform, mobile App and in class sessions with coffee breaks and buffet lunches).

**Members of Latin America cooperation organizations and early inscription (before 30<sup>th</sup> July 2022) will have a 10% discount of the total inscription.**

Program coordination can arrange hotel reservations with cooperation programs for hotels of 3, 4 and 5 stars including the conference hotel.





# MOLECULAR BIOLOGY

Applied to Clinical Oncology

**Note:** hotels and flight tickets are not included in the inscription fee.

Inscription payment can be implemented by credit card (PayPal- online website) or wire transfer.

**Contact information for inscriptions and payments:**

[coordination@internationaloncologydiploma.com](mailto:coordination@internationaloncologydiploma.com)

## Payment

After submitting the online inscription form you will receive a confirmation letter with payment instructions, by e-mail.

Participants are always responsible for the payment of the tuition fee, even if the employer or an organization will pay the tuition fee. Participants are requested to forward the invoice to our financial department and to make sure the tuition fee is paid before the deadline.

## Cancellation Policy

If you have registered but are unable to attend, a substitute delegate is welcome at no extra charge. Please, inform the program coordination in advance by E-mail.

- Cancellations must be sent by E-mail to the program coordination.
- A cancellation/administration fee of 300 USD will be charged in all cases of cancellation before September 1<sup>st</sup>, 2022.
- In case of cancellation after September 1<sup>st</sup>, 2022, no refund will be possible, and the full amount will remain due.

## Fellowships

Each year, the program provides an invaluable opportunity to participate in the program.

Each Fellowship is a stimulating challenge for talented young oncologists or in related areas who seek leading careers in oncology areas in public institutions.

Fellowships cover tuition fee and accommodation in Lima-Peru. All additional costs – travel expenses, subsistence, etc. – are at the participants' expense.

Applicants who meet each of the following requirements will be considered for a complete or partial Fellowship:



# MOLECULAR BIOLOGY

Applied to Clinical Oncology

- You have not attended the program in the past
- You are currently working in public institutions in oncology area
- Limited economic resources to cover the inscription fees

If you are interested in registering for the fellowship program, please make sure you read the Participant Profile to ensure you are eligible for the fellowship.

## To submit your fellowship application, you need to send the following documents:

1. A letter of motivation (max. 400 words!), with a focus on academic excellence and ambitions to pursue a successful oncology areas career. Why should we choose you? Also make sure that you explain why you have a particular interest in molecular oncology area and the reasons for a fellowship application?
2. A curriculum vitae (résumé), including:
  - A list of educational institutes attended + corresponding dates
  - Degree(s) obtained or expected to obtain
  - Work experience + corresponding dates of employment for each position held
  - Research experience + a complete list of publications
3. A copy of diplomas with stamps and/or certification from the institute concerned
4. Two recent letters of recommendation
5. A copy of your passport

Reception of documents must be sent by email to:

[coordination@internationaloncologydiploma.com](mailto:coordination@internationaloncologydiploma.com)

Please note that we only accept and assess complete application packages!

**Application Deadline: 15 of July 2022.** You will be informed about the outcome of the selection procedure by the end of August the latest.



## Europe Founder Coordinator and Professor



Guy Jerusalem MD., PhD is head of medical oncology, director of the breast clinic and research coordinator in medical oncology at University Hospital Center (CHU) in Liège, Belgium. Professor of medical oncology at University of Liège (ULg). Principal investigator in the International Breast Cancer Study Group (IBCSG), the Breast Group of the European Organization for Cancer Research and Treatment (EORTC) and the Breast Cancer International Research Group (BCIRG). Steering committee of several international clinical studies including CONFIRM, SOLE, Bolero 3, Aphinity, SNAP, Bolero 6 and Monaleesa 3. Co-author of 8 book chapters and author of articles published extensively in international journals such as Lancet Oncology, Journal of Clinical Oncology, Blood, The Oncology, Hematology, Annals of Oncology, Clinical, Cancer Research, Cancer Treatment Reviews, Breast Cancer, Journal of the National Cancer Institute, European Journal of Cancer, among others.

## Latin America Founder Coordinator



María del Carmen Cabezas MD., PhD, did her specialty studies and PhD at the University of Liège-Belgium (ULg), with a training in Epidemiology at the Erasmus University (Rotterdam-The Netherlands), and Problem Based Learning at Maastricht University, is General Manager of Health & Research Services, main professor in the Faculty of Medicine of the Pontifical Catholic University of Ecuador. At the publication level, she is board member of Science Direct Group and the International Journal of HIV/AIDS Prevention, peer reviewer of several international journals with a high impact factor such as AIDS & Behavior, Peer J, among others. Researcher and Coordinator of clinical studies of phase I-IV, epidemiological, pharma-economic and public health researches. She has several publications in international journals as main author and co-author in epidemiology, public health, and pharma-economic topics. Her main interest is the development of international education programs with European and Canadian organizations in support of the education system in Latin America.



# MOLECULAR BIOLOGY

Applied to Clinical Oncology

## Coordinator and Professor



Guy Berchem MD., PhD, founder and head of Experimental Cancer Research Laboratory at Health Institute of Luxembourg (LIH). President of the Luxembourg Institute of Cancer (INC) and holds a clinical position leading the oncology platform at Hospital Medical Center of Oncology in Luxembourg. He has more than 70 international scientific publications as author and co-author.

## Program Modality:

In class sessions, with established academic meetings (Saturday and Sunday) on the dates specified in the program. The training of the participants is complemented by online education tools on the ZOOM visual platform. All participants will have total access to the training through videos, teleconferences and educational materials.

The virtual program will be available on-line ([www.internationaloncologydiploma.com](http://www.internationaloncologydiploma.com)) and by mobile app (Molecular Oncology), to assure a complete program access.

## Faculty:

- Adelin Albert M.Sc., PhD. Professor Emeritus at Liege University (ULg). Professor at the Erasmus Summer Course (ESP) program, Netherlands Institute for Health Sciences (NIHES), University of Rotterdam, Netherlands.
- Ahmad Awada MD. Head of the Oncology Medicine Department at Jules Bordet Cancer Institute Brussels, Belgium.
- Guy Berchem MD., PhD. Medical oncologist at the Hospital Center of Luxembourg (CHL), head of the research laboratory Experimental Hemato-Oncology Laboratory (LHCE) at the Public Health Research Center (CRP-Santé) in Luxembourg, president of the National Cancer Institute (INC) and past president of the Luxembourg Oncology Society (SLO).
- Pierre Close M.Sc., PhD. Principal Investigator of FNRS, head of the Laboratory of Cancer Signaling at GIGA Institute and professor at ULg.
- Jacques De Grève MD., PhD. Head of medical oncology and Head of Laboratory of Molecular Oncology at the Free University of Brussels (ULB), ex-President of the Belgian Society of Medical Oncology (BSMO). President of the Belgian Working party for the Development of National Cancer Guidelines. Professor Emeritus of medical oncology at ULB, Belgium.
- Piet Dirix MD., PhD. Associate Professor at University of Antwerp (Belgium) from August 2014, Associate Professor at KU Leuven (Belgium) from August 2013 and staff member at Iridium Cancer Network (Antwerp, Belgium) from May 2014.
- Pierre Frères MD., PhD. Medical Oncologist, and Researcher at CHU of Liège, Belgium.



# MOLECULAR BIOLOGY

Applied to Clinical Oncology

- Christine Gennigens MD., PhD Head of clinics at CHU of Liège and member of the medical council at CHU of Liège, Belgium.
- Enrique Grande, MD., Msc., PhD, has been recently appointed as Director of the Medical Oncology Program and Clinical Research lead at the MD Anderson Madrid International Cancer Center, Spain.
- Michael Herfs BSc., MSc., PhD. He holds a PhD in biomedical and pharmaceutical sciences. Scientific collaborator in Teletife, FNRS of Belgium and ULg, Belgium.
- Catherine Herremans MD. She is a medical oncologist at the Centre Hospitalier in Luxemburg. Her main work experience is in Clinical trials phase I at Cliniques Universitaires Saint-Luc, Brussels, Belgium.
- Guy Jerusalem MD., PhD. Head of oncology at CHU of Liège, professor at ULg and local principal investigator for the International Breast Cancer Study Group (IBCSG), the Breast Group of the European Organization for Cancer Research and Treatment (EORTC) and the Breast Cancer International Research Group (BCIRG).
- Antonio Llombart MD., PhD Doctor in medicine and specialist in Medical Oncology. He is currently head of the Medical Oncology Service at the Arnau de Vilanova Hospital in Valencia and full professor of Clinical Oncology at the Catholic University of Valencia, Spain.
- Agnès Noël M.Sc., PhD. Recognized Belgian researcher. Director of the research center Interdisciplinary Cluster in Applied Genoproteomics (GIGA)-cancer, Belgium.
- Elisa Onesti MD., PhD She currently works as a medical oncologist at the IRCCS “Regina Elena” National Cancer Institute in Rome, Italy. Specialized in Oncology at the University of Rome Sapienza in Italy.
- Marc Peeters MD., PhD. Professor of oncology and CEO at the Antwerp University, Belgium. He is head of the oncology department at the Antwerp University Hospital and coordinator of the Multidisciplinary Oncology Center Antwerp. He is also chairman of the College of Oncology.
- Brieuc Sautois MD., PhD. Head and professor of Clinics in the department of medical oncology at CHU of Liège, board of the oncology certification, Belgium.

## Short Curriculum Vitae of Program Professors

### Adelin Albert M.Sc., PhD



Prominent Belgian professor. He retired as an Emeritus Professor in 2013 but he is still involved in teaching and consultancy activities for universities and hospitals. His research interests include multivariate logistic regression, survival analysis, clinical decision-making, quality control and epidemiology. He acquired a wide experience in the development and application of statistical methods in medicine and biomedical sciences. Author or co-author of over 600 international scientific articles in the field of biostatistics and medical computing in prestigious journals.




## Ahmad Awada, MD



Ahmad Awada is Head of the Oncology Medicine Department at Jules Bordet Cancer Institute Brussels, Belgium. He did a specialization in Internal Medicine and Medical Oncology at Jules Bordet Institute, in Brussels, until 1992. He stayed in the Netherlands (New Drug Development Office, Free University, Amsterdam) and in San Antonio, USA (Institute for Drug Development). He focused on the clinical development of new anticancer agents. He has an important clinical activity in the treatment of solid tumors and in particular breast cancer. Dr Awada took an active part in the development of new drugs (cytotoxics, molecular-targeted therapies, immunotherapy), some of them already widely used. Dr Awada is member of several international scientific societies (ASCO, EORTC, ESMO) and Professor of Clinical Medicine and Medical Oncology at the Université Libre de Brussels. He has published 28 book chapters and 314 peer-reviewed articles in international publications.

## Pierre Close M.Sc., PhD



Principal Investigator of National Fund for Scientific Research (FNRS), head of the Laboratory of Cancer Signaling Group of Applied Genoproteomics (GIGA) and professor at the University of Liège (ULg), Belgium. He has had a great interest in new mechanisms promoting tumor adaptation to identify novel therapeutic strategies in the treatment of invasive or resistant human cancers. Author and co-author of many international scientific publications in high impact factor journals such as: Nature, Cell, Oncogene, Journal of Biological Chemistry among others.

## Jacques De Grève MD., PhD



Head of medical oncology and head of the laboratory of molecular oncology at the Hospital of Free University of Brussels (ULB), Belgium, editor in chief of the Belgian journal of medical oncology, chairman of the Belgian working party for the development of national cancer guidelines. He is professor of medical oncology and coordinator of a course “Molecular Targets in Cancer” at the ULB, Belgium, as well as coordinator of a national interuniversity postgraduate course in medical oncology. He has a special interest in genomic-driven translational therapeutic studies. He has more than 150 international scientific publications in high impact factor journals.



## Piet Dirix MD., PhD



Associate Professor at University of Antwerp (Belgium) from August 2014, Associate Professor at KU Leuven (Belgium) from August 2013 and staff member at Iridium Cancer Network (Antwerp, Belgium) from May 2014. He obtained his PhD in medical sciences (KU Leuven, Belgium) and a specialist in radiation oncology (KU Leuven, Belgium). Professor in international ESTRO courses. Editorial board member: Belgian Journal of Medical Oncology (BJMO) and World Journal of Radiology (WJR). Author and co-author of several publications in prestigious journals. During 2021 he acted as sub investigator with relevant trials such as Oligorecurrent Prostate Cancer and Radiation oncology. Recently, he had the training ICH GCP in this current 2022.

## Pierre Frères MD., PhD



Oncology Specialist. Physician in the clinical oncology department of the University Hospital Center (CHU) of Liège, Belgium. In 2018 he finished his PhD at the Interdisciplinary Cluster Research Center for Applied Genoproteomics (GIGA) in Liège, Belgium, his thesis topic was "The role of circulating microRNA in breast cancer". He has 21 international publications in oncology as author and co-author.

## Christine Gennigens MD., PhD



Head of clinics at University Hospital Center (CHU) of Liège, Belgium and researcher of clinical trials. She is currently involved in the daily clinical management of patients with solid tumors, focusing particularly on genitourinary, gynecological, sarcoma and rare tumors. Also, she is local Principal Investigator and sub-investigator at CHU of Liège, Belgium Trials research Unit, Medical Oncology Department. She has more than 30 scientific publications as author and coauthor.



## Enrique Grande Pulido MD., Msc., PhD



Enrique Grande, MD., Msc., PhD., Director of the Medical Oncology Program and Clinical Research lead at the MD Anderson Madrid International Cancer Center. He is focus on the research on Genitourinary and Endocrine tumors and takes active collaboration in the development of the Translational Research and Early Drug Development Unit. He was awarded his PhD for a pharmacokinetic and pharmacodynamic study of tyrosine kinase inhibitors in liver metabolism, and he holds a master's degree in the molecular biology of cancer from the Spanish National Cancer Research Centre (CNIO). He has published as author more than 150 manuscripts in peer-reviewed journals. In addition, Dr Grande is also the founder of the Spanish group for research on orphan and uncommon tumors (GETHI). Professor at the Francisco de Vitoria University, editor of several international journals. He has participated in the most recent trials in the field of RCC that led to the approval of the new drugs we have now available.

## Michäel Herfs M.Sc., PhD



PhD in biomedical and pharmaceutical sciences. Scientific collaborator in Tel-life, Belgian National Fund for Scientific Research (FNRS), University of Liège (ULg). He completed his post-doctorate in the laboratory of Professor Christopher Crum at Harvard University (Brigham and Women's Hospital, Boston). Since 2006, his interest has focused on microenvironment/origin and HPV tumors. He has more than 40 international publications in high impact factor journals.

## Catherine Herremans, MD



Medical Oncologist at the Centre Hospitalier in Luxemburg. Her main work experience is: Clinical research, early clinical trials, involved in conducting and manage the phase I clinical studies, with pharmaceutical companies at Cliniques Universitaires Saint-Luc, Brussels, Prof J-P Machiels. Dr. Herremans has a specialization in Internal Medicine focused on Hematology and Medical Oncology in palliative care at the State Medical Chamber of Baden-Württemberg in Germany.



## Antonio Llobart Cussac MD., PhD



Doctor in medicine and specialist in Medical Oncology. He is currently head of the Medical Oncology Service at the Arnau de Vilanova Hospital in Valencia and full professor of Clinical Oncology at the Catholic University of Valencia, Spain. With more than 5 years of academic training and research in France and the United States, he is an international expert in breast cancer, with more than 90 indexed publications in the last 5 years. Involved in different Breast Cancer research groups, he is a founding partner and senior-expert at MedSIR (2012), a company dedicated to promoting high-impact clinical research in collaboration with the scientific community, pharmaceutical and biotech companies.

## Agnès Noël M.Sc., PhD



Agnès Noël M.Sc., PhD Recognized Belgian researcher. Director of the research center Interdisciplinary Cluster in Applied Genoproteomics (GIGA)-cancer. President of the thematic graduate school in experimental cancerology of the National Fund for Research (FNRS) of Belgium. Professor of molecular cell biology and molecular oncology and president of the council of research and valorization in health sciences at the University of Liege (ULg). Author and co-author of more than 160 international scientific articles.

## Elisa Onesti Concetta MD., PhD



She currently works as a medical oncologist at the IRCCS “Regina Elena” National Cancer Institute in Rome, Italy. Specialized in Oncology at the University of Rome Sapienza in Italy. She holds a Doctorate in Biomedical and Pharmaceutical Sciences from the University of Liege in Belgium. Experience in Medical Oncology, in management of Clinical Trials as Sub-Investigator, in translational and fundamental research in cancer. Author and co-author of more than fifty articles and summaries. She has carried out preclinical research at the Gustave Roussy Cancer Institute, INSERM Unit U981, Villejuif, France. From 2017 to 2021 she was oncologist at the CHU in Liège, Belgium.



## Marc Peeters MD., PhD



Marc Peeters is Professor of oncology and CEO at the Antwerp University, Belgium. He is head of the oncology department at the Antwerp University Hospital and coordinator of the Multidisciplinary Oncology Center Antwerp. He is also chairman of the College of Oncology. Previously, he was Coordinator of the Digestive Oncology Unit at the University Hospital in Ghent, Belgium. He completed his medical studies at the Catholic University in Leuven, Belgium. He underwent additional training in Oncology and Digestive Oncology at the UZ Gasthuisberg, the Institut Gustave Roussy in Villejuif, Paris, the University of Pennsylvania Hospital in Philadelphia, the Royal Marsden Hospital in London, and the Memorial Sloan-Kettering Cancer Center in New York.

## Brieuc Sautois MD., PhD



Head and professor of clinics at the department of oncology, local Principal Investigator, and sub-investigator at University Hospital Center (CHU) of Liège, researcher of clinical trials of phase I-IV. He is currently involved in the daily clinical management of patients with solid tumors with interest in those of the urinary tract and head and neck. He has more than 40 international scientific publications as author and co-author.



## Attendance and Participation in the Program – Regulations

Participants must complete a minimum of 50% in attendance for in class sessions and 80% in self-learning program, online courses, module exams and tutorial activities to access the final exam. To successfully complete the program, a minimal of 80% must be achieved. Any violation of the stipulated ethic code entails the immediate withdrawal from the program.

## General Program

<b>TOPICS:</b>
Head and neck cancer
Bladder cancer
Prostate cancer
Metastatic cancer of the uterus (cervical and endometrial cancer)
Biological basis of clear cell renal cell carcinoma (CCRCC)
Patient selection for different treatments in metastatic renal cancer
Biology of cancer: Viral carcinogenesis
CNS primary tumors
Pancreatic cancer
New targets and innovative approaches in medical oncology breast cancer
Cardiotoxicity of systemic anticancer therapy
Somatic Mutations
Precision Medicine
Adjuvant and metastatic colon cancer
Gastric Cancer
Hereditary cancers and rare cancers
ER pos HER2 negative breast cancer: standard adjuvant therapy, ER pos ABC: Endocrine monotherapy versus combined treatment approaches, mechanism of endocrine therapy resistance role of CDK4-6 inhibitors, Everolimus and new promising targeted agents, side effect management
Workshop: Clinical cases ER positive HER2 negative breast cancer
PI3K pathway
Cancer stem cells
Minimal residual disease
Systemic mechanism of resistance to therapy
Workshop: clinical case(s) clinical management of rare cancers
Oligometastatic cancer: a new disease entity
From seed and soil to pre-metastatic niche concepts
Angiogenesis and lymphangiogenesis
Ovarian cancer



# MOLECULAR BIOLOGY

Applied to Clinical Oncology

TOPICS
Cancer-Associated Fibroblasts: what is new?
Matrix metalloproteinases: turning clinical failure to innovative perspectives
HER2 positive advanced breast cancer: standard therapies for HER2 positive ABC: optimal sequence and expected outcome, mechanisms of resistance to therapy, new promising drugs
Workshop: clinical cases HER2 positive or triple negative breast cancer
Melanoma BRAF V600 mutations current standards, new approaches
EGFR mutated NSCLC
NSCLC ALK mutations and other drivers
Workshop NSCLC
Triple negative breast cancer part: subgroups and potential targets for therapy, role of PARP inhibitors, new promising drugs, standard therapy in the adjuvant and metastatic setting
Biostatistics
Workshop: publication of scientific data in oncology
How to create posters or publications for conferences
News from ESMO and ASCO in Breast cancer and questions related to breast cancer courses
News from ESMO (2022) and ASCO (2022) in Lung Cancer
Liver Cancer
Thyroid Cancer
Role of immunotherapy in SCLC and non-metastatic NSCLC
Role of immunotherapy in metastatic NSCLC

## Virtual Platform

A personalized e-learning platform will support the access to the contents of each module with their respective evaluations and certifications. In addition, a mobile application tool will provide an interactive webinars access.